Table 1 Baseline clinical characteristics by patient BOR category

From: A gut microbial signature for combination immune checkpoint blockade across cancer types

Characteristics

Best response

P

cPD (n = 21)

PD (n = 30)

SD (n = 29)

PR (n = 22)

CR (n = 4)

Histology cohort

GYN

6 (28.6%)

12 (40.0%)

9 (31.0%)

7 (31.8%)

2 (50.0%)

0.18

NEN

5 (23.8%)

5 (16.7%)

14 (48.3%)

6 (27.3%)

2 (50.0%)

 

UGB

10 (47.6%)

13 (43.3%)

6 (20.7%)

9 (40.9%)

0 (0%)

 

No. of prior systemic therapies

Mean (s.d.)

1.43 (0.811)

1.60 (1.22)

1.97 (1.61)

2.00 (1.23)

1.00 (0.82)

0.32

Median (min, max)

1 (0, 3)

1 (0, 5)

2 (0, 5)

2 (1, 5)

1 (0, 2)

 

Measurable tumor (mm)

Mean (s.d.)

115 (82.3)

72.6 (48.4)

84.1 (53.8)

90.0 (78.2)

70.0 (19.1)

0.49

Median (min, max)

108 (17.0, 344)

58.0 (24.0, 219)

77.0 (17.0, 220)

64.0 (11.0, 325)

77.5 (42.0, 83.0)

 

Age (years)

Mean (s.d.)

59.1 (13.9)

56.5 (15.1)

59.9 (14.3)

56.3 (12.5)

65.3 (9.29)

0.85

Median (min, max)

65.0 (20.0, 75.0)

62.5 (26.0, 75.0)

60.0 (22.0, 82.0)

53.5 (38.0, 74.0)

64.0 (57.0, 76.0)

 

Sex

Female

9 (42.9%)

22 (73.3%)

17 (58.6%)

17 (77.3%)

4 (100%)

0.048

Male

12 (57.1%)

8 (26.7%)

12 (41.4%)

5 (22.7%)

0 (0%)

 

Site

AUS

2 (9.5%)

8 (26.7%)

5 (17.2%)

7 (31.8%)

0 (0%)

0.34

BLA

2 (9.5%)

7 (23.3%)

4 (13.8%)

3 (13.6%)

0 (0%)

 

BMO

4 (19.0%)

1 (3.3%)

3 (10.3%)

1 (4.5%)

0 (0%)

 

MON

8 (38.1%)

6 (20.0%)

11 (37.9%)

3 (13.6%)

2 (50.0%)

 

PMC

5 (23.8%)

8 (26.7%)

6 (20.7%)

8 (36.4%)

2 (50.0%)

 

Season

Autumn

9 (42.9%)

13 (43.3%)

12 (41.4%)

11 (50.0%)

1 (25.0%)

0.8

Spring

3 (14.3%)

2 (6.7%)

7 (24.1%)

2 (9.1%)

1 (25.0%)

 

Summer

5 (23.8%)

10 (33.3%)

5 (17.2%)

5 (22.7%)

2 (50.0%)

 

Winter

4 (19.0%)

5 (16.7%)

5 (17.2%)

4 (18.2%)

0 (0%)

 

BMI (kg m−2)

Mean (s.d.)

26.1 (5.74)

27.2 (5.30)

28.6 (6.23)

25.7 (5.05)

25.6 (3.49)

0.97

Median (min, max)

25.1 (19.1, 38.2)

28.2 (18.6, 37.0)

28.2 (18.9, 48.2)

25.0 (18.8, 35.3)

24.6 (22.8, 30.5)

 

PPIs (<8 weeks)

Yes

14 (66.7%)

9 (30.0%)

8 (27.6%)

7 (31.8%)

3 (75.0%)

0.017

No

7 (33.3%)

21 (70.0%)

21 (72.4%)

15 (68.2%)

1 (25.0%)

 

Antibiotics (<8 weeks)

Yes

3 (14.3%)

1 (3.3%)

3 (10.3%)

2 (9.1%)

0 (0%)

0.65

No

18 (85.7%)

29 (96.7%)

26 (89.7%)

20 (90.9%)

4 (100%)

 

Platelets (×109 l−1)

Mean (s.d.)

297 (134)

279 (81.1)

224 (97.8)

287 (118)

283 (50.1)

0.32

Median (min, max)

302 (87.0, 603)

273 (133, 575)

189 (62.0, 431)

276 (144, 559)

300 (211, 321)

 

Albumin (g l−1)

Mean (s.d.)

30.9 (5.66)

35.0 (5.34)

36.2 (4.34)

35.7 (3.47)

37.0 (2.16)

0.0056

Median (min, max)

32.0 (20.0, 38.0)

36.5 (20.0, 44.0)

37.0 (24.0, 44.0)

36.0 (29.0, 41.0)

36.5 (35.0, 40.0)

 

NLR

Mean (s.d.)

10.7 (15.8)

3.33 (1.99)

3.24 (2.18)

3.66 (2.57)

2.74 (0.144)

0.0033

Median (min, max)

5.27 (2.22, 66.0)

2.92 (0.970, 10.7)

2.72 (1.00, 10.0)

3.27 (0.960, 9.80)

2.70 (2.62, 2.95)

 

LDH (U l−1)

Mean (s.d.)

380 (208)

277 (155)

264 (143)

480 (696)

283 (59.2)

0.89

Median (min, max)

296 (149, 945)

215 (162, 898)

219 (128, 912)

302 (140, 3,440)

295 (202, 339)

 
  1. Clinical characteristics (metadata) are reported stratified by BOR category for microbiome-evaluable participants (n = 106). Numerical metadata are summarized with both means and median values, and statistical associations with BOR (an ordinal variable increasing from cPD to CR) were computed using the Kendall τ test. Categorical metadata were analyzed using frequency tables, with statistical associations with BOR computed using the chi-squared test.
  2. AUS, Austin Hospital (Melbourne); BLA, Blacktown Hospital (Sydney); BMO, Border Medical Oncology (Albury); MON, Monash Hospital (Melbourne); PMC, Peter MacCallum Cancer Centre (Melbourne); BMI, body mass index; PPIs, proton-pump inhibitors; LDH, lactate dehydrogenase.
Back to article page